Qiagen (NYSE:QGEN) NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.
The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions. In the diagnostics arena, Qiagen develops and markets molecular tests for infectious diseases, oncology markers and hereditary disorders, supporting both centralized laboratories and point-of-care settings.
Founded in 1984 and headquartered in Hilden, Germany, Qiagen operates in more than 30 countries across the Americas, Europe, the Middle East, Africa and the Asia-Pacific region. Over the years, the company has expanded its global footprint through strategic partnerships, collaborations with academic institutions and targeted acquisitions aimed at enhancing its molecular testing capabilities and broadening its technology platform.
Qiagen is led by Chief Executive Officer Thierry Bernard, under whose stewardship the company continues to invest in research and development, strengthen its supply-chain resilience and pursue digital initiatives to support data-driven insights. With a strong focus on innovation and quality, Qiagen serves a diverse customer base, including clinical laboratories, biopharmaceutical companies and life-science researchers worldwide.
